In this issue:
Carfilzomib, compared to bortezomib, extends overall survival in multiple myeloma
Concomitant dexamethasone dosing schedule reduces bortezomib-induced peripheral neuropathy
Daratumumab plus pomalidomide and dexamethasone in multiple myeloma
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
Pomalidomide/ Bortezomib combination therapy for patients with relapsed Lenalidomide RRMM
Efficacy of Pembrolizumab, pomalidomide for relapsed MM
Infectious complications in MM patients receiving autologous stem cell transplantation
NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma
Prognostic value of sequencing-based minimal residual disease detection
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity
Please login below to download this issue (PDF)